Libipower Plus
Audience: Consumers, pharmacists
Haloteco and FDA notified healthcare professionals and consumers of a nationwide voluntary recall of Libipower Plus. Lab analysis of Libipower Plus samples were found to contain undeclared Tadalalafil, an active ingredient of FDA approved drugs for Erectile Dysfunction (ED). Tadalalafil may interact with nitrates found in some prescription drugs such as nitroglycerin, and may lower blood pressure to dangerous levels. Additionally, the product may cause side effects, such as headaches and flushing. Libipower Plus is sold as a 1 capsule blister pack through distributors and retail stores in California. Customers who have this product in their possession should stop using it immediately and contact their physician if they have experienced any problems that may be related to taking this product.
[07/13/2009 - Press Release - Haloteco]
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.